Infant Bacterial Therapeutics AB

📍 Stockholm, Sweden🗓 Founded 2013👥 14 employees💰 Last funded 2018
Pharmaceutical Manufacturing🌐 ibtherapeutics.com
Website LinkedIn
IBT is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is developing drug candidate IBP-9414 to prevent NEC in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT has an additional project in its portfolio, a second rare disease program, IBP-1016, for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available. Find more information about Infant Bacterial Therapeutics AB by visiting our website: www.ibtherapeutics.com Feel free to contact us at info@ibtherapeutics.com
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2013
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Infant Bacterial Therapeutics AB?
Infant Bacterial Therapeutics AB has 1 investors on record on gritt.io, 1 mid-stage.
When did Infant Bacterial Therapeutics AB last raise funding?
The most recent investment in Infant Bacterial Therapeutics AB recorded on gritt.io was in 2018.
When was Infant Bacterial Therapeutics AB founded?
Infant Bacterial Therapeutics AB was founded in 2013.
What industry is Infant Bacterial Therapeutics AB in?
Infant Bacterial Therapeutics AB operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Infant Bacterial Therapeutics AB based?
Infant Bacterial Therapeutics AB is headquartered in Stockholm, Sweden.